Impact of bone marrow involvement on early positron emission tomography response and progression‐free survival in the HD18 trial for patients with advanced‐stage Hodgkin lymphoma-Reference-Cited by-同舟云学术

Impact of bone marrow involvement on early positron emission tomography response and progression‐free survival in the HD18 trial for patients with advanced‐stage Hodgkin lymphoma

Published:2021-12-20 Issue: Volume: Page:
ISSN:0007-1048
Container-title:British Journal of Haematology
language:en
Short-container-title:Br J Haematol

Author:

Kreissl Stefanie¹,Voltin Conrad‐Amadeus²^ORCID,Kaul Helen¹,Bühnen Ina¹,Mettler Jasmin²,Pabst Thomas³⁴,Eichenauer Dennis A.¹^ORCID,Fuchs Michael¹,Diehl Volker¹,Dietlein Markus²,Engert Andreas¹,Borchmann Peter¹,Kobe Carsten²

Affiliation:

1. First Department of Internal Medicine and German Hodgkin Study Group (GHSG) Centre for Integrated Oncology Aachen – Bonn – Cologne – Düsseldorf (CIO ABCD) Faculty of Medicine and University Hospital Cologne University of Cologne Cologne Germany

2. Department of Nuclear Medicine Faculty of Medicine and University Hospital Cologne University of Cologne Cologne Germany

3. Department of Medical Oncology Bern University Hospital University of Bern Bern Switzerland

4. Swiss Group for Clinical Cancer Research (SAKK) Bern Switzerland

Funder

Deutsche Krebshilfe

Staatssekretariat für Bildung, Forschung und Innovation

Publisher

Wiley

Subject

Hematology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/bjh.17997

Reference15 articles.

1. Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin's lymphoma (HD15 trial): a randomised, open-label, phase 3 non-inferiority trial

2. Randomized Phase III Trial of ABVD Versus Stanford V With or Without Radiation Therapy in Locally Extensive and Advanced-Stage Hodgkin Lymphoma: An Intergroup Study Coordinated by the Eastern Cooperative Oncology Group (E2496)

3. PET-guided treatment in patients with advanced-stage Hodgkin's lymphoma (HD18): final results of an open-label, international, randomised phase 3 trial by the German Hodgkin Study Group

4. PET-guided eBEACOPP treatment of advanced-stage Hodgkin lymphoma (HD18): follow-up analysis of an international, open-label, randomised, phase 3 trial

5. Bone marrow manifestations of Hodgkin's disease